AGEN
Agenus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Significant Inflow of Main Funds
Consensus Rating "Strong Buy"
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AGEN
Agenus Inc.
An immuno-oncology company with a broad pipeline targeting cancer and infectious disease
3 Forbes Road, Lexington, Massachusetts 02421
--
Agenus Inc., founded in 1994, is a Delaware limited liability company. The company is a clinical-stage biotechnology company specializing in the development of therapies that activate the human immune system to fight cancer and infection.
Earnings Call
Q1/2025
Estimate EPS-1.98
Actual EPS-1.03
Estimate Revenue21.98M
Actual Revenue24.07M
Agenus Q1 2025: Unpacking Contradictions in FDA Strategy, CRC Focus, and Facility Value
May 20,2025 06:09
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AGEN has released its 2025 Q3 earnings. EPS was reported at 1.94, versus the expected 2.2, missing expectations. The chart below visualizes how AGEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AGEN has released its 2025 Q3 earnings report, with revenue of 30.23M, reflecting a YoY change of 20.40%, and net profit of 63.91M, showing a YoY change of 195.09%. The Sankey diagram below clearly presents AGEN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
